drugset / Trial / NCT02687763

Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant

NCT02687763

Phase 0 Completed 5 enrolled Medical University of South Carolina
NaSingle-groupOpen-labelOther

Summary

A prospective, multisite study to evaluate the Impact of Measles, Mumps, Rubella and Varicella ProQuad® vaccination in pediatric patients 6-24 months of age who are being considered and/or evaluated for any solid organ transplant (heart, liver or kidney)

Timeline

Start
2015-12
Primary completion
2016-11-03
Completion
2016-11-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ProQuad Vaccine 0.5 ml Intramuscular